LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Smartphone-Powered, Saliva-Based COVID-19 Diagnostic Test Delivers Lab-Quality Results to App in 20 Minutes

By LabMedica International staff writers
Posted on 18 Jun 2020
Print article
Illustration
Illustration
A portable, saliva-based COVID-19 diagnostic test will be able to detect COVID-19 infection in less than 20 minutes, with an easy-to-use device that can be employed in a variety of settings.

The COVID-19 diagnostic test called Atlas is being developed by Nicoya (Ontario, Canada) with funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). Nicoya will receive up to USD 299,190 in funding to develop the portable COVID-19 diagnostic test that will expand testing capabilities in centralized settings (such as hospital and testing laboratories) as well as point-of-care settings (such as local clinics and long-term care homes).

The development of an Atlas prototype is currently underway at Nicoya. The company is leveraging its deep expertise in areas such as nanotechnology, microfluidics and biochemistry to develop Atlas as a viable solution for containing COVID-19 and preventing the spread of future viral diseases. Atlas will be a single-use, disposable device that will detect active infection by testing for SARS-CoV-2 viral proteins. To make the test as accessible as possible, Nicoya is powering it with smartphone technology so that it can deliver lab-quality results to an app in less than 20 minutes. The test will be performed with a saliva sample, rather than the more common nasopharyngeal swab samples. With Atlas, Nicoya hopes to make testing more available everywhere, from remote communities to front-line screening procedures.

“Our government is mobilizing resources to combat COVID-19 and I’m proud that Nicoya was one of four Phase I funding recipients of the Point-of-Care Diagnostic Test Kit Challenge,” said Raj Saini, Member of Parliament for Kitchener Centre. “Nicoya is an exemplary company already working hard on pioneering innovative research and finding solutions together, and this approach is a pillar to ensuring we have both short and long-term solutions to fight the COVID-19 pandemic.”

Related Links:
Nicoya

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.